Market Tracker

03/24 5:16pm ET

Celgene Corp (NASDAQ:CELG)

123.38
Delayed Data
As of Mar 24
 +0.16 / +0.13%
Today’s Change
94.42
Today|||52-Week Range
127.64
+6.59%
Year-to-Date
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valean...
Mar 22 / Zacks.com - Paid Partner Content
Trump, Biogen and Amgen Hammer Healthcare ETFs
Mar 20 / Zacks.com - Paid Partner Content
Infinity Pharma Focuses on Cancer Drug: Competition Looms
Mar 21 / Zacks.com - Paid Partner Content
Why Biotech Stock Gilead (GILD) Could Be a Value Trap
Mar 20 / Zacks.com - Paid Partner Content
Biotech Bull Making a Comeback
Mar 21 / Zacks.com - Paid Partner Content
Amgen's Repatha Meets Primary Endpoint in Phase III Study
Mar 14 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close123.22
Today’s open123.72
Day’s range122.95 - 124.13
Volume2,845,493
Average volume (3 months)4,250,692
Market cap$96.0B
Dividend yield--
Data as of 3:59pm ET, 03/24/2017

Growth & Valuation

Earnings growth (last year)+28.35%
Earnings growth (this year)+21.50%
Earnings growth (next 5 years)+22.00%
Revenue growth (last year)+22.70%
P/E ratio49.6
Price/Sales8.51
Price/Book14.56

Competitors

 Today’s
change
Today’s
% change
LLYEli Lilly and Co-0.24-0.28%
BMYBristol-Myers Squibb+0.12+0.22%
GSKGlaxoSmithKline0.000.00%
ABBVAbbVie-0.03-0.05%
Data as of 4:03pm ET, 03/24/2017

Financials

Next reporting dateApril 27, 2017
EPS forecast (this quarter)$1.63
Annual revenue (last year)$10.9B
Annual profit (last year)$2.0B
Net profit margin18.30%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Mark J. Alles
President, Chief Operating Officer &
Director
Jacqualyn A. Fouse
Corporate headquarters
Summit, New Jersey

Forecasts